Find Prajmaline manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Prajmalium, N-propylajmaline, 35080-11-6, 75934ud4gj, Ajmalanium, 17,21-dihydroxy-4-propyl-, (17r,21-alpha)-, N-propylajmalinium
Molecular Formula
C23H33N2O2+
Molecular Weight
369.5  g/mol
InChI Key
UAUHEPXILIZYCU-ALHOSYKFSA-N
FDA UNII
75934UD4GJ

Prajmaline
A derivative of the rauwolfia alkaloid AJMALINE. It is an anti-arrhythmia agent but may cause liver damage.
1 2D Structure

Prajmaline

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1R,9R,10S,12R,13S,14R,15R,16S,17S,18R)-13-ethyl-8-methyl-15-propyl-8-aza-15-azoniahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol
2.1.2 InChI
InChI=1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19-,20-,21+,22+,23+,25-/m0/s1
2.1.3 InChI Key
UAUHEPXILIZYCU-ALHOSYKFSA-N
2.1.4 Canonical SMILES
CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O
2.1.5 Isomeric SMILES
CCC[N@@+]12[C@H]3C[C@@H]([C@@H]([C@H]1O)CC)[C@H]4[C@@H]2C[C@@]5([C@H]3N(C6=CC=CC=C65)C)[C@@H]4O
2.2 Other Identifiers
2.2.1 UNII
75934UD4GJ
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bitartrate, Prajmaline

2. Bitartrate, Prajmalium

3. N-propylajmaline

4. Neo Gilurytmal

5. Neo-gilurytmal

6. Neogilurytmal

7. Prajmaline Bitartrate

8. Prajmalium

9. Prajmalium Bitartrate

2.3.2 Depositor-Supplied Synonyms

1. Prajmalium

2. N-propylajmaline

3. 35080-11-6

4. 75934ud4gj

5. Ajmalanium, 17,21-dihydroxy-4-propyl-, (17r,21-alpha)-

6. N-propylajmalinium

7. Prajmalium Ion

8. Prajmalium Cation

9. Prajmalum

10. N(sup 4)-propylajmalinium

11. Unii-75934ud4gj

12. Prajmaline [mi]

13. Prajmalium [who-dd]

14. (17r,21-alpha)-17,21-dihydroxy-4-propylajmalanium

15. Chebi:135560

16. Zinc252462538

17. Db13555

18. Q7238143

19. Ajmalanine, 17,21-dihydroxy-4-propyl-, (17r,21.alpha.)-

20. (1r,9r,10s,12r,13s,14r,15r,16s,17s,18r)-13-ethyl-8-methyl-15-propyl-8-aza-15-azoniahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol

2.4 Create Date
2014-08-25
3 Chemical and Physical Properties
Molecular Weight 369.5 g/mol
Molecular Formula C23H33N2O2+
XLogP32.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count3
Exact Mass369.254203300 g/mol
Monoisotopic Mass369.254203300 g/mol
Topological Polar Surface Area43.7 Ų
Heavy Atom Count27
Formal Charge1
Complexity642
Isotope Atom Count0
Defined Atom Stereocenter Count10
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Anti-Arrhythmia Agents

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)


4.2 ATC Code

C - Cardiovascular system

C01 - Cardiac therapy

C01B - Antiarrhythmics, class i and iii

C01BA - Antiarrhythmics, class ia

C01BA08 - Prajmaline


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty